Connect Biopharma Holdings (CNTB)
(Delayed Data from NSDQ)
$1.02 USD
+0.01 (1.20%)
Updated Aug 23, 2024 03:53 PM ET
3-Hold of 5 3
B Value D Growth A Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CNTB 1.02 +0.01(1.20%)
Will CNTB be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CNTB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CNTB
Are Medical Stocks Lagging Bausch Health (BHC) This Year?
Is Connect Biopharma Holdings (CNTB) Stock Outpacing Its Medical Peers This Year?
CNTB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Connect Biopharma Holdings (CNTB) Outperforming Other Medical Stocks This Year?
Has Connect Biopharma Holdings (CNTB) Outpaced Other Medical Stocks This Year?
Connect Biopharma Holdings Limited Sponsored ADR (CNTB) Upgraded to Buy: What Does It Mean for the Stock?
Other News for CNTB
Connect Biopharma Executives Transition to New Roles
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Leadership Expertise and Strategic Focus Poise Connect Biopharma for Commercial Success
Connect Biopharma Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Connect Biopharma Announces New Leadership and Chair of the Board of Directors